All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

nafamostat 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
proteolytic enzyme inhibitors	1867	81525-10-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nafamostat mesilate nafamostat mesylate FUT-175 nafamostat nafamstat nafamostat dihydrochloride nafamostat hydrochloride nafamostat HCl ronastat	inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic; RN given refers to parent cpd Molecular weight: 347.38 Formula: C19H17N5O2 CLOGP: 2.30 LIPINSKI: 0 HAC: 7 HDO: 5 TPSA: 138.07 ALOGS: -4.01 ROTB: 5

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	5.71 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	81.96 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.84 hours	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	0 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	-0.410		High	0.83
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.902		High	0.83
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	0.692	10^-6 cm/s	High	0.83
dh-clint	Dog hepatocyte intrinsic clearance	8.204	uL/min/10^6 cells	High	0.83
dppb	Dog plasma protein binding (% unbound)	10.510	%	High	0.83
fcs-ppb	Fetal calf serum protein binding (% unbound)	43.250	%	High	0.83
herg	hERG pIC50	4.686	pIC50	High	0.83
hh-clint	Human hepatocyte intrinsic clearance	19.099	uL/min/10^6 cells	High	0.83
hlm-clint	Human liver microsomal intrinsic clearance	22.961	uL/min/mg protein	High	0.83
hppb	Human plasma protein binding (% unbound)	19.640	%	High	0.83
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FGFR1,FLT3,GRK2,GSK3B,IGF1R,IKBKB,INSR,IRAK1,ITK,JAK1,JAK2,JAK3,KIT,MAP2K1,MAP2K6,MAP3K1,MAP3K10,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK10,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70	86
kinase-selectivity-class	ACVR2A,ACVR2B,AURKC,AXL,CAMK2D,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,MAP2K3,MAP2K6,MAP3K11,MAP3K21,MAPK12,MAPK7,MARK4,MINK1,PDK4,RIPK1,SGK1,SIK2,STK10,STK33,TEK,TNIK,TTK,UHMK1,ULK1	31
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	5.224		High	0.83
mh-clint	Mouse hepatocyte intrinsic clearance	44.875		High	0.83
mppb	Mouse plasma protein binding (% unbound)	9.320		High	0.83
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	5.546		High	0.83
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	23.820	%	High	0.83
rh-clint	Rat hepatocyte intrinsic clearance	37.239	uL/min/10^6 cells	High	0.83
rh-fuinc	Rat hepatocyte fraction unbound in incubation	45.580	%	High	0.83
rppb	Rat plasma protein binding (% unbound)	21.480	%	High	0.83
solubility-dd	Solubility at pH 7.4 in DMSO	85.901	uM	High	0.83

Approvals:

Date	Agency	Company	Orphan
None	PMDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Off label use	64.55	48.64	49	333	638286	41982667

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Off label use	69.48	48.75	63	617	1500122	109088497

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D000700	Analgesics
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D000925	Anticoagulants
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006401	Hematologic Agents
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents
MeSH PA	D011480	Protease Inhibitors
MeSH PA	D014361	Trypsin Inhibitors
MeSH PA	D015842	Serine Proteinase Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D018689	Sensory System Agents
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D051056	Complement Inactivating Agents
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:231911	renoprotective agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Cystic fibrosis	indication	190905008	DOID:1485

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.81	Basic
pKa2	10.12	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Tryptase alpha/beta-1	Enzyme	Q15661	TRYB1_HUMAN	INHIBITOR	IC50	10		IUPHAR	IUPHAR
Complement C1r subcomponent	Enzyme	P00736	C1R_HUMAN	INHIBITOR	IC50	6		CHEMBL	IUPHAR
Trypsin-1	Enzyme	P07477	TRY1_HUMAN	INHIBITOR	IC50	7.77		CHEMBL	IUPHAR
Coagulation factor X	Enzyme	P00742	FA10_HUMAN		IC50	4.68		CHEMBL
Suppressor of tumorigenicity 14 protein	Enzyme	Q9Y5Y6	ST14_HUMAN		Ki	10.70		CHEMBL
Complement C1s subcomponent	Enzyme	P09871	C1S_HUMAN		IC50	6.85		CHEMBL
Acid-sensing ion channel 2	Ion channel	Q16515	ASIC2_HUMAN	BLOCKER	IC50	4.20		IUPHAR
Acid-sensing ion channel 1	Ion channel	P78348	ASIC1_HUMAN	BLOCKER	IC50	4.90		IUPHAR
Acid-sensing ion channel 3	Ion channel	Q9UHC3	ASIC3_HUMAN	BLOCKER	IC50	5.60		IUPHAR
Serine protease hepsin	Enzyme	P05981	HEPS_HUMAN		Ki	9.28		CHEMBL
Hepatocyte growth factor activator	Enzyme	Q04756	HGFA_HUMAN		Ki	7.60		CHEMBL
Alpha-ketoglutarate-dependent dioxygenase FTO	Enzyme	Q9C0B1	FTO_HUMAN		IC50	4.86		CHEMBL
Transmembrane protease serine 2	Enzyme	O15393	TMPS2_HUMAN	INHIBITOR	IC50	7		IUPHAR
Plasminogen	Enzyme	P00747	PLMN_HUMAN		IC50	6.62		CHEMBL
Coagulation factor XII	Enzyme	P00748	FA12_HUMAN		Ki	6.98		CHEMBL
Prothrombin	Enzyme	P00734	THRB_HUMAN		IC50	6.54		CHEMBL
Kallikrein-1	Enzyme	P06870	KLK1_HUMAN		IC50	6.19		CHEMBL
Cationic trypsin	Enzyme		TRY1_BOVIN		IC50	7.77		CHEMBL

External reference:

ID	Source
D01670	KEGG_DRUG
82956-11-4	SECONDARY_CAS_RN
C0207683	UMLSCUI
CHEBI:135466	CHEBI
CHEMBL273264	ChEMBL_ID
CHEMBL3989553	ChEMBL_ID
DB12598	DRUGBANK_ID
C032855	MESH_SUPPLEMENTAL_RECORD_UI
4413	PUBCHEM_CID
4262	IUPHAR_LIGAND_ID
5682	INN_ID
Y25LQ0H97D	UNII
7RF	PDB_CHEM_ID
Y25LQ0H97D	INXIGHT DRUGS

Pharmaceutical products:

None